Clinical Trial Update: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating remibrutinib versus placebo for adults with chronic inducible urticaria inadequately controlled by H1-antihistamines.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inducible Urticaria

Drugs mentioned

• Remibrutinib (remibrutinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Inducible Urticaria | Phase 3 | Status: ACTIVE_NOT_RECRUITING